| Entry |
|
|---|
| Name |
Dalfampridine (USAN);
Fampridine (JAN/INN);
4-Aminopyridine;
Neurelan (TN);
Ampyra (TN);
Fampyra (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C5H6N2
|
|---|
| Exact mass |
94.0531
|
|---|
| Mol weight |
94.1145
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Remark |
|
|---|
| Efficacy |
Convulsant inducer, Potassium channel blocker |
|---|
| Disease |
Multiple sclerosis [DS: H01490] |
|---|
| Comment |
Multiple sclerosis symptomatic treatment
|
|---|
| Target |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N07 OTHER NERVOUS SYSTEM DRUGS
N07X OTHER NERVOUS SYSTEM DRUGS
N07XX Other nervous system drugs
N07XX07 Fampridine
D04127 Dalfampridine (USAN) <US>
USP drug classification [BR:br08302]
Central Nervous System Agents
Multiple Sclerosis Agents
Dalfampridine
D04127 Dalfampridine (USAN)
Target-based classification of drugs [BR:br08310]
Ion channels
Voltage-gated ion channels
Potassium channels
KCNA
D04127 Dalfampridine (USAN) <US>
KCNB
D04127 Dalfampridine (USAN) <US>
KCNC
D04127 Dalfampridine (USAN) <US>
KCND
D04127 Dalfampridine (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D04127
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D04127
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D04127
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 7
1 C8x C 21.6064 -17.8079
2 C8x C 21.6064 -19.2083
3 N5x N 22.8220 -19.9085
4 C8x C 24.0305 -19.2083
5 C8x C 24.0305 -17.8079
6 C8y C 22.8220 -17.1078
7 N1a N 22.8239 -15.7075
BOND 7
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 6 1 1
7 6 7 1
|
|---|
